Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05998135 · ClinicalTrials.gov registry record · Phase 2
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
A Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05998135: Recruiting Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, sponsored by Emory University.
NCT05998135 is a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 28 participants, below the 43-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05998135, a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Ovarian High Grade Serous Adenocarcinoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Primary Outcome
Will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median PFS will be estimated using the Brookmeyer-Crowley approach.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- DRUG Atovaquone
- PROCEDURE Paracentesis
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT05998135 shows while recruiting
NCT05998135 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 43-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Platinum-Resistant Ovarian Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT05998135 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05998135 about?
NCT05998135 is a clinical study titled "Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer". This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the gr...
What is the current status of trial NCT05998135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-11-09. Estimated completion is 2027-06-30.
What conditions does trial NCT05998135 study?
This clinical trial studies the following conditions: Platinum-Resistant Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma.
What interventions are being tested in trial NCT05998135?
The interventions under investigation include: Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Atovaquone (DRUG), Paracentesis (PROCEDURE).
Who is sponsoring clinical trial NCT05998135?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05998135 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-Resistant Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05998135's enrollment target sits among peer trials
28 11th of 13 higher than 2 of 13 other Platinum-Resistant Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Platinum-Resistant Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
RECRUITING · Phase 2
-
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RECRUITING · Phase 2
-
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI